Experimental Gene Transfer Procedure to Treat Alpha 1-Antitrypsin Deficiency
|Study Design:||Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
|Official Title:||Preclinical & Phase I/II Trials of AAV-AAT Vectors: Phase I Trial of Intramuscular Injection of a Recombinant Adeno-Associated Virus Alpha 1-Antitrypsin (rAAV2-CB-hAAT) Gene Vector to AAT-Deficient Adults|
- Arm circumference [ Time Frame: Measured at Day 3 ]
- Presence of rAAV2-CB-hAAT vector in blood and semen [ Time Frame: Measured at Day 14 ]
- Serum chemistries, hematology, urinalysis, immune response, and pulmonary function [ Time Frame: Measured at Day 90 ]
- Human AAT levels and phenotype in the blood [ Time Frame: Measured at Day 180 ]
- Adverse events [ Time Frame: Measured at Year 1 and at yearly follow-up evaluations over 15 years ]
|Study Start Date:||March 2004|
|Estimated Study Completion Date:||October 2021|
|Estimated Primary Completion Date:||October 2021 (Final data collection date for primary outcome measure)|
rAAV2-CB-hAAT Gene Vector
Genetic: rAAV2-CB-hAAT Gene Vector
Participants will attend a 5-day inpatient visit, during which they will receive a series of injections consisting of one of four different doses of rAAV2-CB-hAAT.
AAT deficiency is a genetic disorder in which individuals have inadequate levels of the AAT protein. AAT protects the lungs from white blood cell enzymes that can damage air sacs within the lungs, potentially leading to emphysema. Experimental gene transfer procedures, in which normal copies of genes are inserted into cells, are being developed to treat many genetic diseases, including AAT deficiency. In this study, a modified virus, adeno-associated virus (AAV), has been genetically engineered to contain a normal copy of the AAT gene. When AAV is combined with the AAT gene, the resulting agent, rAAV2-CB-hAAT, is able to carry normal copies of the AAT gene into muscle cells to produce additional AAT. The purpose of this study is to evaluate the safety of injecting rAAV2-CB-hAAT into individuals with AAT deficiency.
This 13-month study will enroll individuals with AAT deficiency. Participants currently using AAT protein replacement will discontinue its use for 15 weeks during the study. Participants will first attend a baseline study visit, which will include a medical history review; a physical examination; an electrocardiogram (ECG) to record heart activity; blood, urine, and semen collection; pulmonary function tests; and chest and arm scans. Participants will then attend a 5-day inpatient visit, during which they will receive a series of injections consisting of one of four different doses of rAAV2-CB-hAAT. Physical examinations will occur on all 5 inpatient days; pulmonary function testing, arm circumference measurements, and collection of blood, urine, and semen will occur on selected days of the inpatient stay. Follow-up study visits, with possible overnight stays, will occur on Days 14 and 90. On Days 30, 45, 60, 75, 180, 270, and 365, participants will have blood drawn at a local clinic. On these same days, study staff will contact participants by telephone to review their medical history and symptoms. Unused blood and semen samples will be frozen and stored for future research purposes. Participants will have yearly follow-up evaluations by either telephone or mail for a total of 15 years.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00377416
|United States, Florida|
|University of Florida, College of Medicine, Department of Pediatrics|
|Gainesville, Florida, United States, 32610|
|Principal Investigator:||Terence R. Flotte, MD||Departments of Pediatrics, Molecular Genetics and Microbiology, Powell Gene Therapy Center, University of Florida|